Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10002621 | 0.85 | AGTR1 (0.51) | AGTR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5445315 | 0.79 | L3MBTL1 (0.57) | AGTR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14595048 | 0.79 | AGTR1 (0.53) | AGTR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18584655 | 0.77 | FFAR4 (0.52) | AGTR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2732076 | 0.76 | FABP3 (0.50) | AGTR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL28184674 | 0.76 | AGTR1 (0.60) | AGTR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17297375 | 0.75 | HTR6 (0.67) | AGTR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29357508 | 0.75 | HTR6 (0.67) | AGTR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL27958054 | 0.75 | MEN1 (0.83) | MEN1KMT2AALOX5HTR6KDM4E | |
| SCHEMBL10003163 | 0.74 | NOD1 (0.53) | AGTR1PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| EP-2081892-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | Queen's University at Kingston (CA) | 2009-07-29 | — | — | EP | disclosed |
| EP-2069455-A1 | TERPENE, TERPENOID, AND FULLERENE STABILIZERS FOR FLUOROOLEFINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008058402-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008027514-A1 | TERPENE, TERPENOID, AND FULLERENE STABILIZERS FOR FLUOROOLEFINS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-1893576-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-03-05 | — | — | EP | disclosed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
| WO-2006125324-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | AGTR1 4008/4885PSEN1 6/4885PSEN2 7/4885 |
| US-20070015813-A1 | Treatment of protein folding disorders | HSPA5, TTR, TUFM | AGTR1 4033/4885PSEN1 208/4885PSEN2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.